- Roche’s MabThera (rituximab) is used to treat various types of cancer.
- In this case, NHS will fund the use of MabThera SC (subcutaneous) for roughly 2,400 patients in the UK with follicular lymphoma, a type of non-Hodgkin lymphoma.
- The cost-savings to NHS could exceed $4.2 million per year, mainly because of the time saved by not having to prepare and administer intravenous (IV) chemotherapy.
MabThera SC was approved in the UK based on the SABRINA study, which compared how effective and convenient the subcutaneous formulation was compared to traditional IV.
In addition to cost-savings, treating patients with SC versus IV formulations will ease pressure on overburdened chemotherapy costs.